Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 18/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 17/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402182 | 0.89 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6402184 | 0.89 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6404038 | 0.87 | ITGB1 (0.53) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6404033 | 0.87 | ITGB1 (0.53) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6400323 | 0.86 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6400315 | 0.86 | ITGB1 (0.48) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6401876 | 0.86 | ITGB1 (0.57) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6401871 | 0.86 | ITGB1 (0.57) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6150159 | 0.86 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6150162 | 0.86 | ITGB1 (0.49) | ITGA4ITGB1ITGB7ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | claimed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | ITGA4 2/4885ITGB1 4/4885ITGB7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.